Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP477256.RACFA3WbVBaB-qJsHhIKECv3X8kYobVpTU2Bkt_AOxobA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP477256.RACFA3WbVBaB-qJsHhIKECv3X8kYobVpTU2Bkt_AOxobA130_assertion type Assertion NP477256.RACFA3WbVBaB-qJsHhIKECv3X8kYobVpTU2Bkt_AOxobA130_head.
- NP477256.RACFA3WbVBaB-qJsHhIKECv3X8kYobVpTU2Bkt_AOxobA130_assertion description "[We treated 32 patients with Ph1-negative chronic myeloproliferative disorders (CMD) with excessive thrombocytosis with Interferon alpha-2b (IFN alpha-2b): 26 had essential thrombocythaemia, ET (18 previously untreated, eight pretreated); one thrombocythaemia after treatment for Hodgkin's disease (HD); two thrombocythaemia associated with non-Hodgkin's lymphoma (NHL); three stage II idiopathic myelofibrosis (IM).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP477256.RACFA3WbVBaB-qJsHhIKECv3X8kYobVpTU2Bkt_AOxobA130_provenance.
- NP477256.RACFA3WbVBaB-qJsHhIKECv3X8kYobVpTU2Bkt_AOxobA130_assertion evidence source_evidence_literature NP477256.RACFA3WbVBaB-qJsHhIKECv3X8kYobVpTU2Bkt_AOxobA130_provenance.
- NP477256.RACFA3WbVBaB-qJsHhIKECv3X8kYobVpTU2Bkt_AOxobA130_assertion SIO_000772 2757963 NP477256.RACFA3WbVBaB-qJsHhIKECv3X8kYobVpTU2Bkt_AOxobA130_provenance.
- NP477256.RACFA3WbVBaB-qJsHhIKECv3X8kYobVpTU2Bkt_AOxobA130_assertion wasDerivedFrom befree-20150227 NP477256.RACFA3WbVBaB-qJsHhIKECv3X8kYobVpTU2Bkt_AOxobA130_provenance.
- NP477256.RACFA3WbVBaB-qJsHhIKECv3X8kYobVpTU2Bkt_AOxobA130_assertion wasGeneratedBy ECO_0000203 NP477256.RACFA3WbVBaB-qJsHhIKECv3X8kYobVpTU2Bkt_AOxobA130_provenance.